Two choices of drugs that reduce CV risk in T2DM
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CDMC 2018: Shifting gears in the management of diabetes and CVDBenefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Prof. Eduard Montanya, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: The GLP1 landscape - refining our understanding
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
Prof. Richard Hobbs, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
